melanoma

bees
June 19, 2017

STINGing combination for cancer

A novel immunotherapy combination induced remarkable regression of tumors in a mouse model of head and neck cancer.

By VUMC News and Communications
March 9, 2017

Melanoma study finds new way to enhance targeted therapies

With the help of a drug formerly used to treat HIV/AIDS, researchers at Vanderbilt University Medical Center (VUMC) have found a way to make melanoma cells more vulnerable to targeted anti-cancer therapy.

By Bill Snyder
March 3, 2016

Melanoma response to immune therapy

Melanoma-specific expression of a certain protein identifies tumors that are more responsive to an immune therapy.

By Leigh MacMillan
February 18, 2016

Combining treatments for melanoma

Combining therapies for melanoma that induce cell senescence and that activate the immune response may improve outcomes for patients.

By Leigh MacMillan
October 29, 2015

Investigators find clues to melanoma treatment resistance

Nearly half of all patients with malignant melanoma, the most deadly form of skin cancer, have a mutation in the BRAF gene found in their tumors. Mutations in the BRAF gene turn on a cancer growth switch known as the MAP kinase pathway.

By VUMC News and Communications
March 12, 2015

Gene mutations may predict melanoma response to immunotherapies

Melanoma patients whose tumors test positive for mutations in the NRAS gene were more likely to benefit from new immunotherapy drugs, according to a new study led by Vanderbilt-Ingram Cancer Center (VICC) investigators.

By VUMC News and Communications
January 8, 2015

Study tracks combination therapy to treat melanoma

Melanoma is the most lethal form of skin cancer, with high mortality rates. While new drugs have been approved to treat the disease, patients nearly always develop resistance to the therapies and the cancer advances.
By VUMC News and Communications
November 6, 2014

Immune cell activity and melanoma

The activity of a certain factor in immune cells is essential for an anti-tumor response, emphasizing the need to consider the effects of anti-cancer therapies on immune cells.
By VUMC News and Communications
October 16, 2014

Indiana couple hits the links to support melanoma research

A Vanderbilt-Ingram Cancer Center (VICC) melanoma patient is using his passion for golf to support melanoma research efforts at VICC.
By VUMC News and Communications
June 19, 2014

VICC researchers in spotlight at national cancer conference

New Vanderbilt research suggests patients with advanced melanoma — the most deadly form of skin cancer — could safely benefit from a combination of immunotherapy and targeted therapies aimed at specific gene mutations.
By VUMC News and Communications
December 19, 2013

VU study identifies new gene fusions in melanoma

Cancer researchers, led by investigators at Vanderbilt-Ingram Cancer Center, have identified two novel gene fusions in melanoma that may be responsive to existing cancer therapies. Melanoma is the most deadly form of skin cancer.
By VUMC News and Communications
March 28, 2013

Foundation lauds graduate student’s melanoma research

Katherine Hutchinson, a third-year graduate student in Cancer Biology at Vanderbilt University, has won a $10,000 Research Scholar Award from the Joanna M. Nicolay Melanoma Foundation.
By Bill Snyder
October 25, 2012

Combined drug therapy may delay melanoma progression

Combination therapy with two drugs delayed the development of treatment resistance in patients with metastatic melanoma that expresses a specific mutation in the BRAF gene.
By VUMC News and Communications